![Flexible insulin therapy with a hybrid regimen of insulin degludec and continuous subcutaneous insulin infusion with pump suspension before exercise in physically active adults with type 1 diabetes (FIT Untethered): a single-centre, Flexible insulin therapy with a hybrid regimen of insulin degludec and continuous subcutaneous insulin infusion with pump suspension before exercise in physically active adults with type 1 diabetes (FIT Untethered): a single-centre,](https://www.thelancet.com/cms/attachment/ec11eee2-747c-4aff-a1b1-e6c8527bbf21/gr1.gif)
Flexible insulin therapy with a hybrid regimen of insulin degludec and continuous subcutaneous insulin infusion with pump suspension before exercise in physically active adults with type 1 diabetes (FIT Untethered): a single-centre,
![Genetic studies lead to clinical trial of new treatment for type 1 diabetes | University of Cambridge Genetic studies lead to clinical trial of new treatment for type 1 diabetes | University of Cambridge](https://www.cam.ac.uk/sites/www.cam.ac.uk/files/styles/content-885x432/public/news/news/insulinneedlesheatheraitken.jpg?itok=1nvwSKq7)
Genetic studies lead to clinical trial of new treatment for type 1 diabetes | University of Cambridge
![Once-a-week insulin treatment could be game-changing for patients with diabetes : Newsroom - UT Southwestern, Dallas, Texas Once-a-week insulin treatment could be game-changing for patients with diabetes : Newsroom - UT Southwestern, Dallas, Texas](https://www.utsouthwestern.edu/asset/21e6c572-20e6-4731-9958-b06e3f01c96c/insulin-thumb.jpg)
Once-a-week insulin treatment could be game-changing for patients with diabetes : Newsroom - UT Southwestern, Dallas, Texas
![Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial - The Lancet Diabetes & Endocrinology Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial - The Lancet Diabetes & Endocrinology](https://www.thelancet.com/cms/attachment/c03ab466-aa65-4cb1-b378-fc7f7db842e9/gr1.gif)
Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial - The Lancet Diabetes & Endocrinology
![Once-weekly insulin shot could simplify the future of diabetes treatment | Discovery | UT Southwestern Medical Center Once-weekly insulin shot could simplify the future of diabetes treatment | Discovery | UT Southwestern Medical Center](https://s3-us-west-2.amazonaws.com/utsw-patientcare-web-production/original_images/Diabetes_insulin_600jpg.jpg)
Once-weekly insulin shot could simplify the future of diabetes treatment | Discovery | UT Southwestern Medical Center
![More Evidence Once-Weekly Semaglutide Injection Helps People With Diabetes Lose Weight | Everyday Health More Evidence Once-Weekly Semaglutide Injection Helps People With Diabetes Lose Weight | Everyday Health](https://images.everydayhealth.com/images/more-evidence-semaglutide-helps-people-with-diabetes-lose-at-least-5-percent-of-body-weight-1440x810.jpg)
More Evidence Once-Weekly Semaglutide Injection Helps People With Diabetes Lose Weight | Everyday Health
![The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | SpringerLink The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00125-021-05568-3/MediaObjects/125_2021_5568_Figa_HTML.png)
The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | SpringerLink
![P240 - Insulin Glargine 300 U/mL (Gla-300) provides effective glycemic control in youths with type 1 diabetes (T1D): the EDITION JUNIOR study P240 - Insulin Glargine 300 U/mL (Gla-300) provides effective glycemic control in youths with type 1 diabetes (T1D): the EDITION JUNIOR study](https://services.y-congress.com/congress/Medias/2019/ISPAD2019/423/pdf/poster.png)